CINA-VCF vs Rayvolve

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CINA-VCF

by Avicenna.AI

Rayvolve

by AZmed SAS

AI Verdict

These tools are adjacent in their application, both leveraging AI for diagnostic imaging in radiology. CINA-VCF is specifically designed for detecting vertebral compression fractures on CT scans in adults aged 50 and over. In contrast, Rayvolve provides broader fracture and chest pathology detection on X-rays for both adult and pediatric patients, making the choice dependent on the primary imaging modality and specific diagnostic focus.

Choose CINA-VCF if…

Choose CINA-VCF if your radiology department frequently performs chest and/or abdomen CT scans for various indications and you want to proactively identify unsuspected vertebral compression fractures in adults aged 50 and over. This tool is ideal for improving incidental VCF detection rates, ensuring these often-missed findings are triaged and brought to the attention of clinicians for appropriate follow-up.

View CINA-VCF →

Choose Rayvolve if…

Choose Rayvolve if your facility requires a comprehensive AI solution for rapid and accurate detection of a wide range of fractures and chest pathologies on X-rays for both adult and pediatric patients. This tool is best suited for high-volume environments like emergency departments where reducing interpretation time and diagnostic errors across diverse X-ray studies is paramount.

View Rayvolve →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CINA-VCF	Rayvolve
Pricing	Contact for pricing	Subscription
Deployment	Cloud-based, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker)	On-premise, on cloud, secure local processing and delivery of DICOM images (e.g., PACS); integration via AI marketplace or distribution platform.
FDA Status	1 AI-estimated	1 AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tie

Both tools emphasize seamless integration into existing radiology workflows (PACS/RIS) and aim to reduce interpretation time and diagnostic errors. Rayvolve specifically mentions not requiring any additional clicks from physicians, which suggests a high degree of usability. CINA-VCF also highlights integration with standard reading environments and fast processing times. Without direct user feedback or detailed UI/UX comparisons, it's difficult to definitively pick a winner, hence a tie.

Clinical Value

Rayvolve

While both are FDA-cleared and offer valuable triage capabilities, Rayvolve by AZmed demonstrates broader clinical value. It detects fractures and chest pathologies on X-rays for both adult and pediatric patients (u2265 2 years), including a wide range of pathologies like consolidation, pleural effusion, and pneumothorax. CINA-VCF focuses specifically on detecting unsuspected vertebral compression fractures on CT scans in adults aged 50 and over, making its scope more specialized.

Pricing & Value

Tie

Both tools offer subscription-based pricing models, with CINA-VCF basing it on the number of installations and users, and Rayvolve on the number of analyses, contract duration, and terms. Neither provides transparent pricing details upfront, requiring direct contact for quotes. Without specific pricing information or detailed value propositions beyond general benefits, it is not possible to determine which offers better pricing or overall value.

Enterprise Readiness

Rayvolve

Rayvolve appears to have a slight edge in enterprise readiness due to its broader deployment in over 300 healthcare centers across 21 countries and its compatibility with various AI marketplaces and distribution platforms. CINA-VCF also offers flexible deployment options (cloud, local hardware, virtualized) and integrates with standard reading environments, but Rayvolve's wider global adoption and marketplace presence suggest a more mature enterprise footprint.

Innovation

Tie

Both tools demonstrate innovation in their respective domains. CINA-VCF innovates by detecting unsuspected vertebral compression fractures on routine chest and/or abdomen CT scans, addressing a condition that often goes unnoticed. Rayvolve offers comprehensive AI for X-ray diagnostics, including fracture and chest pathology detection for both adult and pediatric populations, and has expanded its capabilities to include automated orthopedic measurements and bone age estimation. Both leverage deep learning and offer fast processing times, making it a tie in terms of innovative application of AI in medical imaging.

Support & Docs

Tie

Neither the provided structured facts nor the web search results offer specific details about the level of customer support, training, or documentation available for either CINA-VCF or Rayvolve. Both companies are established in the AI healthcare space, implying a certain level of support, but without explicit information, a distinction cannot be made. Therefore, this dimension is a tie.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CINA-VCF	Rayvolve
Name	CINA-VCF	Rayvolve
Target Modality	Chest and/or abdomen CT scans	X-rays
Target Condition(s)	Unsuspected vertebral compression fractures (VCFs)	Fractures and chest pathologies
Target Patient Age	Adults aged 50 years and over	Adult and pediatric patients (u2265 2 years)
Processing Time	10-60 seconds	Less than one minute

Videos

Demos, reviews, and walkthroughs featuring CINA-VCF and Rayvolve.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific types of pathologies and imaging modalities do these AI tools analyze, and for which patient populations?

CINA-VCF focuses on detecting unsuspected vertebral compression fractures on chest and/or abdomen CT scans for adults aged 50 years and over. In contrast, Rayvolve provides automatic detection and localization of fractures and chest pathologies on X-rays for both adult and pediatric patients aged two years and older.

How do these tools integrate into existing radiology workflows and what specific efficiencies can a physician expect?

Both tools integrate with standard PACS and RIS environments, with CINA-VCF offering triage and notification for VCF findings on CT scans within 10-60 seconds. Rayvolve, for X-rays, aims to reduce interpretation time by up to 27% and turnaround time by up to 83% through automatic detection and localization of fractures and chest pathologies.

What are the key clinical benefits and accuracy metrics that differentiate these tools in improving diagnostic confidence and patient care?

CINA-VCF enhances patient outcomes by identifying unsuspected vertebral compression fractures on CT scans, thereby improving workflow for radiologists. Rayvolve focuses on X-rays, demonstrating a reduction in false negatives by up to 67% and overall diagnostic errors, contributing to more rapid and accurate diagnoses for a broader range of pathologies.

What is the expected learning curve for radiologists to effectively utilize these AI tools within their daily practice?

Both CINA-VCF and Rayvolve are designed for seamless integration into existing PACS and RIS workflows, suggesting a minimal learning curve for radiologists. Their primary function is to augment existing processes by providing rapid analysis and notifications, allowing physicians to leverage the AI output within their familiar reading environments.

Do these AI tools provide audit trail capabilities or detailed reporting features for tracking AI-assisted diagnoses and interventions?

The provided information does not explicitly detail specific audit trail or comprehensive reporting features for either CINA-VCF or Rayvolve. However, as medical AI tools, they are typically designed to integrate within existing clinical workflows where such tracking mechanisms are often managed by the PACS/RIS systems.

What are the key considerations for implementing and scaling these AI solutions across multiple hospital sites or a large integrated delivery network?

For CINA-VCF, scalability is supported by its subscription model, which is based on the number of installations and users, allowing for tailored deployment across multiple sites. Rayvolve's integration via AI marketplaces or distribution platforms suggests a framework designed to facilitate broader deployment and management within large healthcare systems.